Naltrexone: a case report of pruritus from an antipruritic.
Intense, generalized pruritus associated with mycosis fungoides was relieved using subcutaneous naloxone but intensified when changed to the new oral opioid antagonist, naltrexone. Rechallenge again led to worsening in pruritus. This unexpected adverse effect is surprising as naltrexone and naloxone are currently thought to work via similar opioid receptor binding. The worsening of the itch may have been due to adaptation in opioid receptor expression induced by prolonged naloxone therapy, possibly highlighting differential opioid receptor affinity between naltrexone and naloxone, or may have represented an idiosyncratic adverse reaction. Naltrexone and naloxone have been reported to reduce pruritus due to cholestasis, uraemia, morphine epidurals, and possibly atopic dermatitis and urticaria. Naltrexone has the convenience of oral administration and a longer half-life. The role of the opioid system and naltrexone in pruritus is reviewed.
Sullivan
J R
JR
Department of Dermatology, Royal Newcastle Hospital, Newcastle, New South Wales, Australia.
Watson
A
A
D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000150:complications*; D009270:Naloxone / Q000627:therapeutic use; D009271:Naltrexone / Q000009:adverse effects* / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology*; D012878:Skin Neoplasms / Q000150:complications*
D009292:Narcotic Antagonists; D009270:Naloxone; D009271:Naltrexone